SNTI — Senti Biosciences Income Statement
0.000.00%
Last trade - 00:00- $86.33m
- $38.16m
- 27
- 21
- 80
- 38
Annual income statement for Senti Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.566 | 2.76 | 4.29 | 2.56 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 25.5 | 43.2 | 65.1 | 95.3 | 61 |
| Operating Profit | -24.9 | -40.5 | -60.8 | -92.7 | -61 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.9 | -55.3 | -49.7 | -83.4 | -52.8 |
| Net Income After Taxes | -19.9 | -55.3 | -49.7 | -83.4 | -52.8 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -19.9 | -55.3 | -58.2 | -71.1 | -52.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19.9 | -55.3 | -58.2 | -71.1 | -52.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.5 | -12.7 | -11.6 | -12.9 | -11.4 |
| Dividends per Share |